SUDO-550 demonstrated favorable safety, tolerability, and once-daily pharmacokinetic profile with full central nervous system (CNS) penetration - Achieved exposure levels associated with >90% ...

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented posters at the 2025 EORTC-NCI ...

FMC-242 is a potentially best-in-class covalent allosteric inhibitor that breaks the interaction between PI3Kα and RAS, targeting the largest ...

Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms ...

Relay Therapeutics, Inc. leads with RLY-2608, an allosteric PI3Kα inhibitor showing superior safety & efficacy. Learn more ...

Esperion announced the expansion of its development portfolio with a new program aimed at treating primary sclerosing cholangitis (PSC), a rare liver disease. The company confirmed the effectiveness ...

– Data support advancement to Phase 2 clinical trial in multiple sclerosis, anticipated in 2H 2025 – SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (ALMS), a clinical stage ...

ATV-1601 is a first-in-class allosteric selective inhibitor of AKT1 E17K Pan-AKT inhibitors offer limited efficacy for patients with AKT1 E17K-driven mutant tumors due to insufficient inhibition of ...

Alumis Inc., a clinical stage biopharmaceutical company, announced that it will present data on its oral therapy A-005, a selective TYK2 inhibitor, at the ACTRIMS Forum 2025 on February 28, 2025.